Differential Analysis of Serum Principal Components Treated with Compound Sophora Decoction and Related Compounds Based on High-Resolution Mass Spectrometry (HRMS)

Table 3

Details of differential compounds between FFKST and M in the positive ion mode.

Rt (min)	Compounds	Formula	[M + H]^experimental	[M + H]^calculated	Error (ppm)	MS/MS
60.41	Docosanamid	C22H45NO	340.3565	340.3574	−2.6	102, 88
62.02	(20R)-Cholesta-3,5-dien	C27H44	369.3501	369.3516	−4	287, 243, 215, 175, 161, 147, 109, 95
37.99	Val-his-ala-gly	C16H26N6O5	383.2033	383.2037	−1.2	327, 281, 267
41.45	Propyl-6-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-2-amino-2-deoxy-α-D-glucopyranoside	C17H32N2O10	425.2118	425.213	−2.8	355, 281
60.21	4-[(2-Cyanoethyl)amino]-3-hydroxy-2,2-dimethyl-4-oxobutyl-palmitate	C25H46N2O4	439.3536	439.353	1.3	407
60.73	3-(1-Hydroxy-2,4-dimethylhexyl)-2-isopropoxy-5,6-dimethoxy-4-pyridinyl diisopropylcarbamate	C25H44N2O6	469.3272	469.3272	0	329, 189
62.21	N-[(1S,2S,8S,8aS)-7-{(2S)-1-[Bis(2-methoxyethyl)amino]-1-oxo-2-propanyl}-8-hydroxy-1,4a-dimethyldecahydro-2-naphthalenyl]-3,3-dimethylbutanamide	C27H50N2O5	483.3782	483.3792	−2.2	453
62.39	N-[(9Z)-9-Octadecen-1-yl]-2-oxohexadecanamide	C34H65NO2	520.5056	520.5088	−6.2	282, 264, 252
61.88	(2R,4S,5S,7S)-5-Amino-N-butyl-7-{4-[4-(dimethylamino)butoxy]-3-(3-methoxypropoxy)benzyl}-4-hydroxy-2,8-dimethylnonanamide	C32H59N3O5	566.4512	566.4527	−2.7	226, 184, 104
60.86	L-Valyl-L-isoleucylglycyl-L-alanyl-N-[(2S)-6-amino-1-oxo-2-hexanyl]-L-lysinamide	C28H54N8O6	599.4247	599.4239	1.3	300
63.68	L-Lysyl-L-seryl-L-leucyl-N5-(diaminomethylene)-L-ornithyl-L-seryl-L-phenylalanyl-L-lysine	C39H68N12O10	865.5265	865.5254	−1.2	780, 721, 597, 575, 145.00